Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $32.95, but opened at $35.08. Zai Lab shares last traded at $34.21, with a volume of 207,702 shares traded.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised Zai Lab to a "strong-buy" rating in a research note on Wednesday, February 5th.

Zai Lab Stock Up 0.8 %

The stock has a 50 day moving average of $27.51 and a 200 day moving average of $25.69. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -12.51 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. As a group, sell-side analysts anticipate that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the transaction, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. This represents a 18.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.88% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Zai Lab during the 4th quarter worth $29,000. Pictet Asset Management Holding SA bought a new position in shares of Zai Lab during the 4th quarter worth $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock worth $1,496,000 after acquiring an additional 1,200 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Zai Lab by 15.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock worth $290,000 after acquiring an additional 1,502 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Zai Lab by 4.2% during the 4th quarter. Invesco Ltd. now owns 44,340 shares of the company's stock worth $1,161,000 after acquiring an additional 1,790 shares during the period. Institutional investors own 41.65% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.